|
|
|
51-200 employees
View all
|
|
Biotechnology
|
|
1100 Winter Street, Waltham, MA 02451, US
|
|
AlloVir | 4,260 followers on LinkedIn. A global leader in allogeneic, off-the-shelf, multi-virus specific T- cell immunotherapies | AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The company’s technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. AlloVir’s technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy.
|
AlloVir Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75%
|
The widely used AlloVir email format is {f}{last} (e.g. [email protected]) with 75% adoption across the company.
To contact AlloVir customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.